0000899866-17-000025.txt : 20170208
0000899866-17-000025.hdr.sgml : 20170208
20170208163910
ACCESSION NUMBER: 0000899866-17-000025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170206
FILED AS OF DATE: 20170208
DATE AS OF CHANGE: 20170208
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000899866
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133648318
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 COLLEGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 2032722596
MAIL ADDRESS:
STREET 1: 100 COLLEGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MACKAY MARTIN
CENTRAL INDEX KEY: 0001414815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-27756
FILM NUMBER: 17583059
MAIL ADDRESS:
STREET 1: PFIZER INC ATTN CORPORATE SECRETARY
STREET 2: 235 EAST 42ND STREET
CITY: NEW YORK
STATE: NY
ZIP: 10017
4
1
wf-form4_148658993769140.xml
FORM 4
X0306
4
2017-02-06
0
0000899866
ALEXION PHARMACEUTICALS INC
ALXN
0001414815
MACKAY MARTIN
C/O ALEXION PHARMACEUTICALS, INC
100 COLLEGE STREET
NEW HAVEN
CT
06510
0
1
0
0
EVP & Global Head of R&D
Common Stock, par value $.0001 per share
2017-02-06
4
S
0
2710
125.69
D
39978
D
Common Stock, par value $.0001 per share
2017-02-06
4
S
0
18
126.88
D
39960
D
This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
/s/ Michael Greco, Attorney-in-Fact for Martin Mackay
2017-02-08